Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial

BackgroundIn the randomized, controlled, phase III KEYNOTE-061 trial, second-line pembrolizumab did not significantly prolong overall survival (OS) versus paclitaxel in patients with PD-L1-positive (combined positive score ≥1) advanced gastric/gastroesophageal junction (G/GEJ) cancer but did elicit...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal for ImmunoTherapy of Cancer Ročník 11; číslo 6; s. e006920
Hlavní autoři:	Shitara, Kohei, Di Bartolomeo, Maria, Mandala, Mario, Ryu, Min-Hee, Caglevic, Christian, Olesinski, Tomasz, Chung, Hyun Cheol, Muro, Kei, Goekkurt, Eray, McDermott, Raymond S, Mansoor, Wasat, Wainberg, Zev A, Shih, Chie-Schin, Kobie, Julie, Nebozhyn, Michael, Cristescu, Razvan, Cao, Z Alexander, Loboda, Andrey, Özgüroğlu, Mustafa
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England BMJ Publishing Group Ltd 01.06.2023 BMJ BMJ Publishing Group LTD BMJ Publishing Group
Edice:	Original research
Témata:	Angiogenesis Antibodies Antibodies, Monoclonal, Humanized Antibodies, Monoclonal, Humanized - therapeutic use Cancer Cancer therapies Cell death Clinical outcomes Clinical/Translational Cancer Immunotherapy Gastric cancer Gastrointestinal Neoplasms Gene expression Gene Expression Profiling Genetic Markers Growth factors Humanized Humans Hypoxia Immunotherapy Medical prognosis Metastasis Monoclonal Monoclonal antibodies Neoplasms. Tumors. Oncology. Including cancer and carcinogens Paclitaxel Paclitaxel - pharmacology Paclitaxel - therapeutic use Patients Programmed Cell Death 1 Receptor RC254-282 Response rates Review boards Stomach Neoplasms Stomach Neoplasms - drug therapy Stomach Neoplasms - genetics Stomach Neoplasms - pathology Targeted cancer therapy Transcriptome Tumors United States > US Programmed Cell Death 1 Receptor Gene Expression Profiling Gastrointestinal Neoplasms Genetic Markers Immunotherapy
ISSN:	2051-1426, 2051-1426
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!